Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.72 |
| ▸ | TGFBR2 | P37173 | 6/20 | 0.66 |
| ▸ | MAP3K20 | Q9NYL2 | 5/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 7/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410956 | 1.00 | TGFBR1 (0.72) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL413352 | 0.99 | TGFBR1 (0.71) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL412629 | 0.94 | TGFBR1 (0.74) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL411955 | 0.91 | TGFBR1 (0.65) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL438229 | 0.90 | TGFBR1 (0.72) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL413540 | 0.87 | TGFBR1 (0.77) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL373689 | 0.84 | TGFBR1 (1.00) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL373782 | 0.83 | TGFBR1 (1.00) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL14189201 | 0.80 | TGFBR1 (0.69) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL373472 | 0.79 | TGFBR1 (1.00) | TGFBR1TGFBR2MAP3K20CYP2D6THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160115447-A1 | COMPOSITIONS AND METHODS FOR IMPROVING INDUCED NEURON GENERATION | HOWARD HUGHES MEDICAL INSTITUTE | 2016-04-28 | — | — | US | disclosed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010033906-A2 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-03-25 | — | — | WO | disclosed |
| US-7368445-B2 | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368445-B2 | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368445-B2 | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070155722-A1 | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155722-A1 | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155722-A1 | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms | ELI LILLY AND COMPANY (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1723146-A1 | FUSED PYRAZOLE DERIVATIVES AS TGF-BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF FIBROSIS AND NEOPLASMS | ELI LILLY AND COMPANY (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005092894-A1 | FUSED PYRAZOLE DERIVATIVES AS TGF-BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF FIBROSIS AND NEOPLASMS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155722-A1 | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms | SMAD3, TGFBR1, TGFBR2 | TGFBR1 2/4885TGFBR2 3/4885MAP3K20 77/4885 |
| US-20160115447-A1 | COMPOSITIONS AND METHODS FOR IMPROVING INDUCED NEURON GENERATION | PLK1, GAP43, NEFM | TGFBR1 2217/4885TGFBR2 1904/4885MAP3K20 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.